REFERENCES
1. Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. Coronavirus pandemic (COVID-19). Our world in data. 2020.
2. Galván Casas C, Catala A, Carretero Hernández G, Rodríguez‐Jiménez P, Fernández‐Nieto D, Rodríguez‐Villa Lario A, et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. British Journal of Dermatology. 2020;183(1):71-7.
3. de Masson A, Bouaziz J-D, Sulimovic L, Cassius C, Jachiet M, Ionescu M-A, et al. Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. Journal of the American academy of dermatology. 2020;83(2):667-70.
4. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al. Pernio-like skin lesions associated with COVID-19: a case series of 318 patients from 8 countries. Journal of the American Academy of Dermatology. 2020;83(2):486-92.
5. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous manifestations of COVID-19: an evidence-based review. American journal of clinical dermatology. 2020;21(5):627-39.
6. Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: A worldwide review. JAAD international. 2021;2:119-33.
7. Marzano AV, Genovese G, Moltrasio C, Gaspari V, Vezzoli P, Maione V, et al. The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. Journal of the American Academy of Dermatology. 2021;84(5):1356-63.
8. Recalcati S, Gianotti R, Fantini F. COVID-19: The experience from Italy. Clinics in Dermatology. 2021;39(1):12-22.
9. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.
10. Hamming I, Timens W, Bulthuis M, Lely A, Navis Gv, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2004;203(2):631-7.
11. Gül Ü. COVID-19 and dermatology. Turkish journal of medical sciences. 2020;50(8):1751-9.
12. Soliman A, Nair AP, Al Masalamani MS, De Sanctis V, Khattab MAA, Alsaud AE, et al. Prevalence, clinical manifestations, and biochemical data of type 2 diabetes mellitus versus nondiabetic symptomatic patients with COVID-19: A comparative study. Acta Bio Medica: Atenei Parmensis. 2020;91(3):e2020010.
13. Iqbal F, Soliman A, De Sanctis V, Mushtaq K, Nair AP, Al Masalamani MA, et al. Prevalence, clinical manifestations, and biochemical data of hypertensive versus normotensive symptomatic patients with COVID-19: a comparative study. Acta Bio Medica: Atenei Parmensis. 2020;91(4).
14. Abuelgasim E, Dona ACM, Sondh RS, Harky A. Management of urticaria in COVID‐19 patients: a systematic review. Dermatologic Therapy. 2021;34(1):e14328.
15. Sachdeva M, Gianotti R, Shah M, Bradanini L, Tosi D, Veraldi S, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. Journal of dermatological science. 2020;98(2):75-81.
16. Pollack Jr CV, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Annals of emergency medicine. 1995;26(5):547-51.